The disability burden of non‐fatal disease is not reflected in allocation of grants
The Medical Research Future Fund (MRFF) has become an increasingly important part of health and medical research funding in Australia. In the 2019–20 federal budget the Australian Government announced $5 billion of research funding over a 10‐year period.1 In comparison, the National Health and Medical Research Council (NHMRC) awarded $923 million in funding in the 2019 funding round.2 An important difference between the NHMRC and MRFF funding schemes is that MRFF grants are usually targeted within funding initiatives. For example, in 2019 there was a $20 million call for ovarian cancer research under the Emerging Priorities and Consumer‐Driven Research Initiative.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Christopher Maher and Rachelle Buchbinder are funded by NHMRC Research Fellowships. They are chief investigator or co‐investigator on multiple previous and current research grants from government agencies and charities in Australia and internationally. They have received travel expenses for speaking at conferences from the professional organisations hosting the conferences. They are investigators on the SHaPED trial which received heat wraps at no cost from Flexeze. The funding sources had no influence on any aspect of study design, data collection, analysis or interpretation, reporting or publication.
No relevant disclosures.